Advertisement
Advertisement

BOLD

BOLD logo

Boundless Bio, Inc. Common Stock

1.63
USD
Sponsored
+0.07
+4.49%
Apr 15, 15:55 UTC -4
Closed
exchange

After-Market

1.62

-0.01
-0.74%

BOLD Earnings Reports

Positive Surprise Ratio

BOLD beat 4 of 8 last estimates.

50%

Next Report

Date of Next Report
May 07, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/
-$0.58
Implied change from Q4 25 (Revenue/ EPS)
--
/
+1.75%
Implied change from Q1 25 (Revenue/ EPS)
--
/
-18.31%

Boundless Bio, Inc. Common Stock earnings per share and revenue

On Mar 09, 2026, BOLD reported earnings of -0.57 USD per share (EPS) for Q4 25, missing the estimate of -0.53 USD, resulting in a -9.35% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.89% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of -0.58 USD, with revenue projected to reach -- USD, implying an increase of 1.75% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Lexaria Bioscience Corp. Common Stock
Report Date
Apr 13, 2026 For Q2 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+38.08%
logo
Quince Therapeutics, Inc. Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$1.92
Actual
-$7.10
Surprise
-268.68%
logo
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
logo
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
logo
Nurix Therapeutics, Inc. Common stock
Report Date
Apr 08, 2026 For Q1 26
Estimate
-$0.76
Actual
-$0.79
Surprise
-2.68%
logo
NovaBridge Biosciences - ADR
Report Date
Apr 07, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.28
Surprise
-421.58%
logo
Scilex Holding Company Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$0.47
Actual
-$2.21
Surprise
-360.99%
FAQ
For Q4 2025, Boundless Bio, Inc. Common Stock reported EPS of -$0.57, missing estimates by -9.35%, and revenue of $0.00, 0% as expectations.
The stock price moved up 0.89%, changed from $1.13 before the earnings release to $1.14 the day after.
The next earning report is scheduled for May 07, 2026.
Based on 4 analysts, Boundless Bio, Inc. Common Stock is expected to report EPS of -$0.58 and revenue of -- for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement